On August 29, 2025, Coya Therapeutics, Inc. announced it received a $4.2 million milestone payment from Dr. Reddy’s Laboratories following FDA acceptance of its drug application for a Phase 2 study on ALS treatment. An additional $4.2 million will be received upon dosing the first patient in the study.